Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6472
-0.0291-4.30%
Post-market: 0.65480.0076+1.17%19:50 EDT
Volume:11.50M
Turnover:7.65M
Market Cap:157.27M
PE:-0.87
High:0.7060
Open:0.6759
Low:0.6400
Close:0.6763
52wk High:3.39
52wk Low:0.1611
Shares:243.00M
Float Shares:214.26M
Volume Ratio:0.22
T/O Rate:5.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-184.82%
PB:-5.42
PE(LYR):-0.36

Loading ...

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)

TIPRANKS
·
Jun 30

Outlook Therapeutics Regains Nasdaq Compliance

MT Newswires Live
·
Jun 29

Outlook Therapeutics Regains NASDAQ Compliance After Shares Hold Above $1 Bid Threshold

Reuters
·
Jun 27

Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application

Dow Jones
·
Jun 16

BUZZ-Outlook Therapeutics rises after US FDA accepts to review eye disease treatment

Reuters
·
Jun 16

Outlook Therapeutics says FDA accepts resubmitted Lytentava BLA for wet AMD review

Reuters
·
Jun 16

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for Ons-5010/Lytenava™ (Bevacizumab-Vikg) as a Treatment for Wet Amd

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Pdufa Target Action Date Set for July 29, 2026

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Initiates Pre-Launch Activities for Ons-5010/Lytenava

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40

Reuters
·
Jun 04

Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase

Reuters
·
Jun 02

Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA

MT Newswires Live
·
Jun 01

Outlook Therapeutics resubmits FDA BLA for Lytneava in wet AMD

Reuters
·
Jun 01

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for Ons-5010/Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics - FDA Says No Additional Trials Required for Lytenava in Namd

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics Prices Offering of Common Shares

MT Newswires Live
·
May 29

Outlook to sell 8.54M shares at 58.55c in registered direct offering

TIPRANKS
·
May 29

Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share

Reuters
·
May 29

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
May 29